{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:50:14Z","timestamp":1790283014212,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The survival time of human immunodeficiency virus (HIV)\u2013infected individuals or patients with acquired immunodeficiency syndrome (AIDS) is influenced by multiple factors. Studying survival and influential factors after antiretroviral therapy (ART) contributes to improving treatment protocols, management strategies, and prognosis for people living with HIV\/AIDS (PLWHA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study collected case data and follow-up records of PLWHA who received ART in Dazu District, Chongqing City, between 2007 and 2022. Cumulative survival rates were calculated using life tables. Survival curves were plotted using the Kaplan\u2013Meier method. Uni-variable and multivariable Cox proportional hazards models analyzed factors influencing survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 5,237 PLWHA receiving ART. Within the first year of ART initiation, 146 AIDS-related deaths occurred, accounting for 29.49% (146\/495) of total deaths. Cumulative survival rates at 1, 5, 10, and 15\u2009years were 0.97, 0.90, 0.85, and 0.79, respectively. During the observation period, male patients who received ART had a 1.89 times higher risk of death compared to females (aHR, 1.89; 95%; CI, 1.50\u20132.37). Patients aged \u226560\u2009years had a 3.44-fold higher risk of death than those aged &amp;lt;30\u2009years (aHR, 3.44; 95% CI, 1.22\u20139.67). Injection drug users (aHR, 4.95; 95% CI, 2.00\u201312.24) had a higher risk of death than those with heterosexual (aHR, 1.60; 95% CI, 0.69\u20133.72) and homosexual transmission. Patients with a baseline CD4+ T lymphocyte count &amp;lt;200 cells\/\u03bcL (aHR, 8.02; 95% CI, 4.74\u201313.57) and between 200 and 349 cells\/\u03bcL (aHR, 2.14; 95% CI, 1.26\u20133.64) had a higher risk of death than those with \u2265350 cells\/\u03bcL. Patients with ART initiation at WHO clinical stage IV had a 2.48-fold higher risk of death than those at stage I (aHR, 2.48; 95% CI, 1.17\u20135.23).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The first year following ART initiation is critical in HIV\/AIDS treatment, emphasizing the need for intensified follow-up and monitoring to facilitate successful immune system reconstruction. Older age, male sex, injection drug use, baseline CD4+ T lymphocyte count &amp;lt;200 cells\/\u03bcL, and WHO clinical stage IV are associated with an increased risk of death. Tailored treatment and management strategies should be implemented for patient populations at higher risk of mortality and with a poorer prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1327264","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:49:15Z","timestamp":1708577355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Survival analysis of PLWHA undergoing combined antiretroviral therapy: exploring long-term prognosis and influencing factors"],"prefix":"10.3389","volume":"12","author":[{"given":"Jun-fan","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"ref1","year":"2022"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1186\/s12889-023-15662-3","article-title":"Survival times of HIV\/AIDS in different AIDS diagnostic and treatment guidelines from 2006 to 2020 in Liuzhou, China","volume":"23","author":"Ke","year":"2023","journal-title":"BMC Public Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s11904-019-00471-4","article-title":"History of the HIV epidemic in China","volume":"16","author":"Wu","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1093\/ije\/dyq217","article-title":"Evolution of information-driven HIV\/AIDS policies in China","volume":"39","author":"Sun","year":"2010","journal-title":"Int J Epidemiol"},{"key":"ref5","first-page":"795","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume-title":"N Engl J Med","author":"Lundgren","year":"2015"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"JC4","DOI":"10.7326\/ACPJC-2015-163-12-004","article-title":"In early HIV infection, immediate vs deferred antiretroviral therapy reduced serious illnesses at 3 years","volume":"163","author":"Smaill","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1586\/14787210.2014.913981","article-title":"Update on antiretroviral treatment during primary HIV infection","volume":"12","author":"Ambrosioni","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref8","volume-title":"National Free Antiretroviral Therapy Handbook for HIV\/AIDS","year":"2016"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e3969","DOI":"10.1097\/MD.0000000000003969","article-title":"Outcomes and factors associated with survival of patients with HIV\/AIDS initiating antiretroviral treatment in Liangshan prefecture, southwest of China: a retrospective cohort study from 2005 to 2013","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"989127","DOI":"10.3389\/fpubh.2022.989127","article-title":"Survival and risk factors associated with mortality in people living with HIV from 2005 to 2018 in Nanjing, China","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Public Health"},{"key":"ref11","first-page":"1509","article-title":"Survival time of HIV\/AIDS cases and related factors in Beijing, 1995-2015","volume":"38","author":"Li","year":"2017","journal-title":"Chin J Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijid.2019.02.016","article-title":"Epidemiological analyses of regional and age differences of HIV\/AIDS prevalence in China, 2004-2016","volume":"81","author":"Qiao","year":"2019","journal-title":"Int J Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12879-023-08165-4","article-title":"Excess mortality and associated factors among people living with HIV initiating highly active antiretroviral therapy in Luzhou, China 2006-2020","volume":"23","author":"Niu","year":"2023","journal-title":"BMC Infect Dis"},{"key":"ref14","first-page":"936","article-title":"Survival analysis on HIV\/AIDS patients who began receiving antiretroviral therapy from 2005 to 2015 in Tianjin","volume":"40","author":"Guo","year":"2019","journal-title":"Chin J Epidemiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1097\/CM9.0000000000001842","article-title":"Prevention and control of HIV\/AIDS in China: lessons from the past three decades","volume":"134","author":"Xu","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"ref16","first-page":"1398","article-title":"Survival time of HIV\/AIDS cases and influencing factors in Gansu province, 1997-2018","volume":"40","author":"Li","year":"2019","journal-title":"Chin J Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1084210","DOI":"10.3389\/fpubh.2023.1084210","article-title":"Clinico-demographic and survival profile of people living with HIV on antiretroviral treatment","volume":"11","author":"Shaik","year":"2023","journal-title":"Front Public Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/cid\/ciu261","article-title":"Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients","volume":"59","author":"Ingle","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"100351","DOI":"10.1016\/j.eclinm.2020.100351","article-title":"Sex differences in HIV treatment outcomes and adherence by exposure groups among adults in Guangdong, China: A retrospective observational cohort study","volume":"22","author":"Li","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4103\/jfmpc.jfmpc_1703_20","article-title":"Factors associated with survival in adult people living with HIV\/AIDS (PLHAs) in Mumbai, India (2004-2019): a retrospective cohort study","volume":"10","author":"Acharya","year":"2021","journal-title":"J Family Med Prim Care"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1086\/515219","article-title":"AIDS and the elderly","volume":"28","author":"Chiao","year":"1999","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"100113","DOI":"10.1016\/j.ssmqr.2022.100113","article-title":"Challenges to meeting the HIV care needs of older adults in the rural south","volume":"2","author":"Quinn","year":"2022","journal-title":"SSM Qual Res Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"Guaraldi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/QAI.0b013e31815b7dba","article-title":"Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients","volume":"46","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(10)60829-X","article-title":"Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs","volume":"376","author":"Altice","year":"2010","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1473-3099(11)70097-4","article-title":"Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study","volume":"11","author":"Zhang","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/cid\/ciw183","article-title":"Mortality according to CD4 count at start of combination antiretroviral therapy among HIV-infected patients followed for up to 15 years after start of treatment: collaborative cohort study","volume":"62","author":"May","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12879-015-0969-x","article-title":"Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada","volume":"15","author":"Patterson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"ref31","first-page":"1138","article-title":"Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal","volume-title":"Clin Infect Dis","author":"Mocroft","year":"2009"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.3402\/gha.v3i0.5398","article-title":"Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia","volume":"3","author":"Alemu","year":"2010","journal-title":"Glob Health Action"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"800839","DOI":"10.3389\/fpubh.2022.800839","article-title":"Higher risk of mortality and Virologic failure in HIV-infected patients with high viral load at antiretroviral therapy initiation: An observational cohort study in Chongqing, China","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Public Health"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1468-1293.2005.00290.x","article-title":"Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine cohort, France, 1996-2002","volume":"6","author":"Bonnet","year":"2005","journal-title":"HIV Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1371\/journal.pmed.0030438","article-title":"Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators","volume":"3","author":"Mills","year":"2006","journal-title":"PLoS Med"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1327264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:49:20Z","timestamp":1708577360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1327264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":35,"alternative-id":["10.3389\/fpubh.2024.1327264"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1327264","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"article-number":"1327264"}}